Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy
L. Dousset(Centre Hospitalier Universitaire de Bordeaux), Lise Boussemart(Centre National de la Recherche Scientifique), M. Beylot‐Barry(Université de Bordeaux), Jacques Rouanet(Centre Hospitalier Universitaire de Clermont-Ferrand), I. Kerneuzet(Hôpital Pontchaillou), B. Vergier(Centre Hospitalier Universitaire de Bordeaux), Sandrine Mansard(Centre Hospitalier Universitaire de Clermont-Ferrand), Séverine Le Roy(Université Paris-Saclay), Célèste Lebbé(Inserm), F. Poizeau(Université Rennes 2), A. Dupuy(Université de Rennes), David Cappellen, Émilie Routier(Université Paris-Saclay), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Charline Caumont(Inserm), Alexa B. Schrock(GlobalFoundries (United States)), Clara Allayous(Inserm), Jean‐Philippe Merlio(Centre Hospitalier Universitaire de Bordeaux), E. Gérard(Université de Bordeaux), Laurent Mortier, Alexandra Lespagnol(Institut de génétique et de développement de Rennes), Maxime Battistella(Peter MacCallum Cancer Centre), A. Greliak(Université de Lille), Siraj M. Ali(UPMC Hillman Cancer Center), Jessica Lee(Foundation Medicine (United States)), Caroline Robert(Institut Gustave Roussy), Marie‐Dominique Galibert(Centre National de la Recherche Scientifique), Solène‐Florence Kammerer‐Jacquet(Inserm)
Cited by 61
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k